Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of the metabolic syndrome according to 2005 American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) scientific statement~* No history of diabetes and 100 \<=LDL-C \<=250 mg/dl~Exclusion Criteria:~* Myocardial Infarction, coronary artery bypass surgery, or angioplasty within 3 months~* Congestive heart failure defined by New York Heart Association (NYHA) class III or IV~* Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins~* Uncontrolled hypertension~* Unstable angina

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Vytorin® (Type: EXPERIMENTAL): simvastatin (+) ezetimibe 10/20 mg (Vytorin®) ; tablet, once daily, 8 Weeks
- atorvastatin (Type: ACTIVE_COMPARATOR): atorvastatin 10 mg; tablet, once daily, 8 Weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).